Pure Global

Study of TDM-180935 in Atopic Dermatitis Patients - Trial NCT06363461

Access comprehensive clinical trial information for NCT06363461 through Pure Global AI's free database. This Phase 2 trial is sponsored by Technoderma Medicines Inc. and is currently Recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06363461
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06363461
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Study of TDM-180935 in Atopic Dermatitis Patients
A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM-180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients

Study Focus

Atopic Dermatitis

TDM-180935 topical ointment 1.0%

Interventional

drug

Sponsor & Location

Technoderma Medicines Inc.

Rolling Meadows,Covington,New Brighton,Anderson,Austin,College Station,Norfolk, United States of America

Timeline & Enrollment

Phase 2

Apr 13, 2024

Oct 31, 2024

24 participants

Primary Outcome

Change in m-EASI (modified Eczema Area and Severity Index) score

Summary

Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis
 Patients

ICD-10 Classifications

Atopic dermatitis
Atopic dermatitis, unspecified
Other atopic dermatitis
Acute atopic conjunctivitis
Allergic contact dermatitis

Data Source

ClinicalTrials.gov

NCT06363461

Non-Device Trial